Corteva (NYSE:CTVA) Price Target Raised to $89.00

Corteva (NYSE:CTVA) had its price objective increased by Royal Bank Of Canada from $80.00 to $89.00 in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Several other brokerages also recently commented on CTVA. Bank of America increased their price objective on shares of Corteva from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Wells Fargo & Company upped their target price on shares of Corteva from $77.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday. Rothschild & Co Redburn reduced their price target on shares of Corteva from $71.00 to $65.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Wall Street Zen upgraded shares of Corteva from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, BNP Paribas Exane increased their target price on Corteva from $70.00 to $72.00 and gave the company a “neutral” rating in a research note on Monday, November 17th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $82.37.

Corteva Stock Performance

Shares of CTVA opened at $72.63 on Thursday. The company has a quick ratio of 1.07, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The stock has a market cap of $49.08 billion, a P/E ratio of 45.97, a P/E/G ratio of 1.84 and a beta of 0.75. The business’s 50 day moving average price is $68.82 and its 200-day moving average price is $68.39. Corteva has a 52 week low of $53.40 and a 52 week high of $77.41.

Corteva (NYSE:CTVA) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The company had revenue of $3.91 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same quarter last year, the company earned $0.32 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Equities research analysts anticipate that Corteva will post 2.96 earnings per share for the current fiscal year.

Corteva Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Monday, March 2nd will be paid a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Monday, March 2nd. Corteva’s dividend payout ratio (DPR) is 45.57%.

Institutional Trading of Corteva

A number of hedge funds have recently bought and sold shares of CTVA. Brighton Jones LLC increased its position in shares of Corteva by 307.2% during the 4th quarter. Brighton Jones LLC now owns 15,588 shares of the company’s stock valued at $888,000 after purchasing an additional 11,760 shares during the last quarter. Woodline Partners LP grew its position in Corteva by 40.3% during the first quarter. Woodline Partners LP now owns 57,919 shares of the company’s stock valued at $3,645,000 after buying an additional 16,644 shares during the period. Wealthcare Advisory Partners LLC bought a new stake in Corteva during the second quarter valued at approximately $213,000. KLP Kapitalforvaltning AS increased its holdings in Corteva by 6.2% during the second quarter. KLP Kapitalforvaltning AS now owns 251,676 shares of the company’s stock valued at $18,757,000 after buying an additional 14,600 shares during the last quarter. Finally, Joel Isaacson & Co. LLC bought a new position in Corteva in the second quarter worth approximately $228,000. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Key Stories Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Several sell‑side firms lifted targets and kept bullish ratings, signaling analyst confidence in longer‑term upside: Deutsche Bank to $90 (buy), Wolfe Research to $86 (outperform), and RBC to $89 (outperform). Deutsche Bank raise Wolfe Research raise RBC raise
• Positive Sentiment: Brokerage consensus remains constructive (consensus “Moderate Buy”), which supports demand for the shares despite near‑term noise. Consensus Moderate Buy
• Positive Sentiment: Strategic commentary highlights Corteva’s expanding role in global agriculture and technology leadership—positive for medium‑term growth expectations. Corteva expands role
• Neutral Sentiment: Analyst views are mixed across publications — some highlight long‑term upside tied to licensing and settlements, while others argue valuation limits near‑term gains. Investors should weigh catalyst timing. Bull case analysis Conflicting analyst views
• Neutral Sentiment: Technical analysis pieces warn of a key structural test — useful for traders but not definitive for fundamentals; could increase short‑term volatility. Technical caution
• Negative Sentiment: Q4 results missed revenue expectations (seasonal timing and weaker crop‑protection/seed demand); revenue miss and a wider loss drove an after‑hours selloff. Those operational misses are the main near‑term headwind. Q4 revenue miss After‑hours fall
• Negative Sentiment: JPMorgan downgraded Corteva from overweight to neutral (citing valuation/limited near‑term upside), which can cool momentum among institutional buyers. JPMorgan downgrade
• Negative Sentiment: Market reaction to the earnings miss (seasonal timing) and mixed guidance elements increases short‑term uncertainty even as analysts argue for longer‑term upside — expect higher intraday volatility. Seasonal timing impact

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.